Company Profile: NEUREN PHARMACEUTICALS LIMITED (ASX: NEU) is under the health care sector and is a biopharmaceutical company with a focus on neurological conditions. Developing drugs for neurological disorders is what the company is engaged into and trofinetide (NNZ-2566) and NNZ-2591 are some of its products. Hamilton Pharmaceuticals Inc. and Neuren Pharmaceuticals Inc. are its subsidiaries. The company’s incorporation year was 2001 and is in Burke Rd, Auckland, Australia.
Start discussion with value Investors for ASX Stock Market Investment and Opinion.
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s
Those phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.
Click here for your FREE Report